Targeting of these oncogenes for cancer therapy is therefore of particular interest, and their specific inhibitors (e.g., erlotinib, vemurafenib, and trametinib, inhibitors of EGFR, BRaf, and MEK, respectively) are currently in clinical use10. This evidence concerns the gene MAP2K7 and cancer.